KR102307276B1 - Tatk―cdkl5 융합 단백질, 그의 조성물, 제형 및 용도 - Google Patents

Tatk―cdkl5 융합 단백질, 그의 조성물, 제형 및 용도 Download PDF

Info

Publication number
KR102307276B1
KR102307276B1 KR1020167026521A KR20167026521A KR102307276B1 KR 102307276 B1 KR102307276 B1 KR 102307276B1 KR 1020167026521 A KR1020167026521 A KR 1020167026521A KR 20167026521 A KR20167026521 A KR 20167026521A KR 102307276 B1 KR102307276 B1 KR 102307276B1
Authority
KR
South Korea
Prior art keywords
ser
leu
cdkl5
pro
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167026521A
Other languages
English (en)
Korean (ko)
Other versions
KR20170002372A (ko
Inventor
엘리자베타 치아니
프랑코 라콘
Original Assignee
알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 filed Critical 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐
Publication of KR20170002372A publication Critical patent/KR20170002372A/ko
Application granted granted Critical
Publication of KR102307276B1 publication Critical patent/KR102307276B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737C-reactive protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022Cyclin-dependent kinase (2.7.11.22)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/405Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020167026521A 2014-02-28 2015-02-27 Tatk―cdkl5 융합 단백질, 그의 조성물, 제형 및 용도 Active KR102307276B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
US61/946,280 2014-02-28
PCT/IB2015/000999 WO2015128746A2 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (2)

Publication Number Publication Date
KR20170002372A KR20170002372A (ko) 2017-01-06
KR102307276B1 true KR102307276B1 (ko) 2021-09-30

Family

ID=53539745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167026521A Active KR102307276B1 (ko) 2014-02-28 2015-02-27 Tatk―cdkl5 융합 단백질, 그의 조성물, 제형 및 용도

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3110837B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3110837T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA202190727A3 (enExample)
ES (2) ES2885245T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE045393T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3110837T (enExample)
MX (2) MX392778B (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689A1 (enExample)
PL (2) PL3608334T3 (enExample)
PT (2) PT3608334T (enExample)
RS (2) RS62244B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3110837T1 (enExample)
SM (2) SMT202100478T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202000537RA (en) * 2014-02-28 2020-03-30 Univ Bologna Alma Mater Studiorum Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2018005617A2 (en) * 2016-06-28 2018-01-04 Alma Mater Studiorum - Universitá Di Bologna TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
TW201927825A (zh) * 2017-11-30 2019-07-16 美商阿米庫斯醫療股份有限公司 Cdkl5 表現變體和cdkl5 融合蛋白
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
AU2021392642A1 (en) 2020-12-01 2023-06-22 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815582A1 (en) * 2010-10-25 2012-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Treatment of mecp2-associated disorders
SG10202000537RA (en) * 2014-02-28 2020-03-30 Univ Bologna Alma Mater Studiorum Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Molecular Therapy, 2008, Vol.17, No.2, pp.334-342
The Journal of Neuroscience, 2010, Vol.30, No.38, pp.12777-12786

Also Published As

Publication number Publication date
PH12016501689B1 (en) 2016-10-03
EP3608334B1 (en) 2021-05-19
AU2015221860B2 (en) 2019-09-12
EP3110837A2 (en) 2017-01-04
AU2015221860A1 (en) 2016-09-08
CR20160392A (es) 2017-06-12
NI201600127A (es) 2017-03-13
DOP2016000220A (es) 2016-12-15
ES2745335T3 (es) 2020-02-28
EP3608334A1 (en) 2020-02-12
SMT202100478T1 (it) 2021-09-14
BR112016019868B1 (pt) 2023-11-28
US10584318B2 (en) 2020-03-10
SV2016005264A (es) 2017-02-15
SG11201606863YA (en) 2016-09-29
HUE045393T2 (hu) 2019-12-30
US10907138B2 (en) 2021-02-02
PH12016501689A1 (en) 2016-10-03
HUE055282T2 (hu) 2021-11-29
DK3608334T3 (da) 2021-08-23
US9944910B2 (en) 2018-04-17
WO2015128746A2 (en) 2015-09-03
PT3608334T (pt) 2021-08-25
RS62244B1 (sr) 2021-09-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
US20150247134A1 (en) 2015-09-03
AU2019219743A1 (en) 2019-09-19
NZ723371A (en) 2023-11-24
ES2885245T3 (es) 2021-12-13
CN106255706A (zh) 2016-12-21
EA202190727A3 (ru) 2021-11-30
IL247481A0 (en) 2016-11-30
US20200199549A1 (en) 2020-06-25
CA2940401C (en) 2022-11-29
MX2016011167A (es) 2017-04-06
IL275435A (en) 2020-08-31
PE20161406A1 (es) 2017-01-14
BR112016019868A2 (pt) 2017-10-17
KR20170002372A (ko) 2017-01-06
ZA201606655B (en) 2020-05-27
CL2016002142A1 (es) 2017-09-08
MX2020001223A (es) 2022-05-31
MX392778B (es) 2025-03-24
CY1124727T1 (el) 2022-07-22
JP2020062022A (ja) 2020-04-23
EA201691691A1 (ru) 2017-05-31
ZA201906304B (en) 2022-03-30
DK3110837T3 (da) 2019-09-16
CA2940401A1 (en) 2015-09-03
US20180327725A1 (en) 2018-11-15
PL3110837T3 (pl) 2020-04-30
JP6896050B2 (ja) 2021-06-30
AU2019219743B2 (en) 2020-10-29
JP6629747B2 (ja) 2020-01-15
WO2015128746A3 (en) 2015-11-26
US9290746B2 (en) 2016-03-22
IL247481B (en) 2020-07-30
HRP20191511T1 (hr) 2019-11-29
US20160194617A1 (en) 2016-07-07
LT3110837T (lt) 2019-10-10
SG10202000537RA (en) 2020-03-30
HRP20211324T1 (hr) 2021-11-26
PT3110837T (pt) 2019-09-12
SI3110837T1 (sl) 2019-12-31
RS59344B1 (sr) 2019-10-31
PL3608334T3 (pl) 2021-11-22
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
JP2017507655A (ja) 2017-03-23
EA038000B1 (ru) 2021-06-22
SI3608334T1 (sl) 2021-11-30
EA202190727A2 (ru) 2021-07-30
SMT201900504T1 (it) 2019-11-13
EP3110837B1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
AU2019219743B2 (en) TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
JP2017507655A5 (enExample)
US20210268072A1 (en) TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
US11603394B2 (en) Targeted effector proteins and uses thereof
WO2020176900A1 (en) Galectin-1/ galectin-3 chimeras and multivalent proteins
HK1226745A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
NZ749459A (en) TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160926

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201229

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210707

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210924

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210924

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240823

Start annual number: 4

End annual number: 4